Literature DB >> 17893691

Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels.

Florencia Halperin1, Ronald J Anderson, Jean E Mulder.   

Abstract

BACKGROUND: A previously healthy 32-year-old man presented with pain in his chest, ankle, and hip. His musculoskeletal pain progressed over the course of 6 months to the point of difficulty with ambulation. INVESTIGATIONS: Radiographic studies included chest and ankle X-rays, multiple bone scans, and foot and pelvic MRI. Laboratory evaluation comprised a serum chemistry panel (including electrolyte levels, renal function tests and liver function tests), and measuring serum levels of phosphorus, parathyroid hormone, vitamin D, alkaline phosphatase, and fibroblast growth factor 23, as well as urine levels of calcium and phosphorus. DIAGNOSIS: Tumor-induced osteomalacia. MANAGEMENT: The patient received phosphate and vitamin D supplementation in the form of potassium-phosphorus (500 mg, three times daily) and calcitriol (0.5 microg, three times daily). Six months after his first presentation, he underwent surgical resection of a rib mass, with subsequent normalization of phosphorus concentration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17893691     DOI: 10.1038/ncpendmet0639

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  8 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  Tumor-induced osteomalacia: experience from a South American academic center.

Authors:  G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano
Journal:  Osteoporos Int       Date:  2017-03-25       Impact factor: 4.507

3.  Varied presentation of sinonasal phosphaturic mesenchymal tumour: report of a case series with follow-up.

Authors:  Regi Kurien; Vedantam Rupa; Meera Thomas
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-16       Impact factor: 2.503

4.  [Reduced bone density and bone pain :osteomalacia with hypophospatemia and hypophosphaturia].

Authors:  H M Findeisen; C J Auernhammer; K G Parhofer; K A Herrmann; C la Fougere; C Weiler; R Bartl; E Koch
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

5.  Successful treatment of tumor-induced osteomalacia causing by phosphaturic mesenchymal tumor of the foot.

Authors:  Shuzhong Liu; Xi Zhou; An Song; Zhen Huo; Yipeng Wang; Weibo Xia; Yong Liu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome.

Authors:  S Kumar; T Diamond
Journal:  Bone Rep       Date:  2020-05-06

7.  FGF-23 transmitted tumor - induced hypophosphatemic osteomalacia: A rare case of a young woman with recurrent fractures and review of the literature.

Authors:  Florian A Frank; Lukas Gerber; Alexander Cornelius; Daniel Baumhoer; Andreas H Krieg
Journal:  J Bone Oncol       Date:  2022-01-29       Impact factor: 4.072

8.  Surgical treatment of recurrent spinal phosphaturic mesenchymal tumor-induced osteomalacia: A case report.

Authors:  Shuzhong Liu; Xi Zhou; An Song; Zhen Huo; Yipeng Wang; Yong Liu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.